COVID-19 mRNA vaccine that can be stored at fridge temperature appears safe and effective

Embargoed until: Publicly released: 2022-11-15 03:00

Australia; International; NSW

Photo by Martin Sanchez on Unsplash

A COVID-19 mRNA vaccine developed by international and Australian researchers that could be more easily distributed in areas with logistical challenges appears safe and effective in its phase 1 trial. The mRNA vaccines currently in use need to be storied in freezers, making it hard to distribute them in countries with limited storage capacity. The ChulaCov19 vaccine can be stored at 2-8 degrees for up to 3 months, making it easier to distribute. 72 volunteers received two doses of the vaccine 21 days apart. The researchers say none of the volunteers had a severe reaction to the vaccine, and they found evidence of a strong antibody and T-cell response which suggests the vaccine may be effective at building COVID-19 protection.

Media release

From:

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Springer Nature, Web page The URL will go live after the embargo ends

Journal/
conference: Nature Microbiology

Research:Paper

Organisation/s: Kirby Institute, UNSW Sydney, Thai Red Cross AIDS Research Centre, Thailand

Funder: This study was funded by National Vaccine Institute (NVI) grant no. 2563.1/11 and 2564.1/4; C2F Fund-Chulalongkorn Academic Advancement into Its 2nd Century Project (CUAASC); the Ratchadapisek Sompoch Endowment Fund (2021), Chulalongkorn University (764002-HE04); and Public Donation through Covid-19 vaccine development fund of the Faculty of Medicine, Chulalongkorn University and the Thai Red Cross Society, Thailand. We thank all the study participants without whose support the study would not have been possible.

Media Contact/s

Contact details are only visible to registered journalists.